Perini, Francesca http://orcid.org/0000-0001-6558-5060
Nazimek, Jadwiga Maria
Mckie, Shane
Capitão, Liliana P. http://orcid.org/0000-0003-3117-5156
Scaife, Jessica
Pal, Deepa
Browning, Michael
Dawson, Gerard R. http://orcid.org/0000-0002-8624-7500
Nishikawa, Hiroyuki
Campbell, Una
Hopkins, Seth C. http://orcid.org/0000-0003-3999-2281
Loebel, Antony
Elliott, Rebecca http://orcid.org/0000-0002-7602-010X
Harmer, Catherine J. http://orcid.org/0000-0002-1609-8335
Deakin, Bill http://orcid.org/0000-0002-2750-962X
Koblan, Kenneth S.
Funding for this research was provided by:
This work was funded by Sumitomo Pharma America Inc. (Marlborough MA, USA).
Article History
Received: 24 July 2023
Accepted: 27 July 2023
First Online: 7 August 2023
Competing interests
: F.P., J.M.N., S.M., L.P.C., J.S., and D.P. have nothing to disclose. M.B., G.R.D., and B.D. are P1vital shareholders. H.N., U.C., S.C.H., A.L., and K.S.K. are employees of Sumitomo Pharma America Inc. C.J.H. has received consultancy payments from P1vital, Lundbeck, Johnson & Johnson, Sage Pharmaceuticals, Zogenix, and Pfizer (all unconnected to the current work). L.P.C. has served as a consultant to P1vital. P1vital was contracted and funded by Sumitomo Pharma America to perform the study in collaboration with the Universities of Manchester and Oxford and the Oxford Health NHS Foundation Trust.